Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.

Jane E RogersKohei YamashitaMatheus Sewastjanow-SilvaErnesto Rosa VicentiniRebecca WatersJaffer A Ajani

Published in: Expert review of anticancer therapy (2023)

Some ESCC patients will not experience a response to ICIs. Determining intrinsic and acquired resistance patterns are needed to further capitalize on ICI therapy for ESCC patients. PD-L1 expression has been explored as a potential biomarker. Data show, however, PD-L1 positive tumor patients benefit but this assessment is not always needed.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
combination therapy
chronic kidney disease
prognostic factors
electronic health record
radiation therapy
deep learning
data analysis
rectal cancer